24/7 Wall Street
22 Sept 2026, 14:51 UTC · 51m ago
Verdict
Headline takes no side. We score MRNA +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Moderna will present detailed Phase 3 data for its personalized cancer therapy intismeran at the ESMO Congress on October 24.
Priced inwell-flagged calendar item
So whatThe binary nature of the hazard ratios and survival curves presented in late October could trigger a sharp multiple compression or a sustained rally.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Moderna reported last month that the 1,137-patient INTerpath-001 melanoma trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
Priced inreported last month
So whatThe current 516% YTD surge is based on this top-line conclusion, but the lack of underlying numbers leaves a valuation gap to be filled by the ESMO data.
More positive than 92% of claims this week
Moderna and Merck are testing the intismeran therapy across nine mid-stage and late-stage studies in other tumor types, including lung, bladder, and renal cancers.
Priced inanalysis of existing programs
So whatSuccess in the melanoma trial provides a clinical reference point that could re-rate the NPV of these eight other oncology programs.
More positive than 76% of claims this week
Moderna stock has risen 516% year-to-date, while rival BioNTech is up only 5%.
Priced inmulti-year trends
So whatThe 511 percentage point divergence confirms the market is betting on intismeran specifically rather than a general mRNA platform re-rating.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The stock has surged over 500% YTD following positive top-line results from a melanoma trial.
More positive than 59% of ticker scores this week
Collaborating on a personalized cancer therapy that met primary and secondary endpoints in a Phase 3 trial.
More positive than 43% of ticker scores this week
The stock is up slightly but is being contrasted unfavorably against Moderna's massive gains.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 78% of relationship scores this week
[mutual] The article identifies BioNTech as Moderna's closest messenger RNA rival.
+5.9%
Price agrees with the score
$183.19 vs $172.94 close before publication (Sep 21) · not market-adjusted
MRNA chart →